Rationale for the use of alpha-blockers in the treatment of benign prostatic hyperplasia (BPH).

Suppr

超能文献

作者信息

Kawabe K, Moriyama N, Yamada S, Taniguchi N

机构信息

Department of Urology, Faculty of Medicine, University of Tokyo, Japan.

出版信息

Int J Urol. 1994 Sep;1(3):203-11. doi: 10.1111/j.1442-2042.1994.tb00036.x.

DOI:10.1111/j.1442-2042.1994.tb00036.x

PMID:7542152

Abstract

摘要

相似文献

Rationale for the use of alpha-blockers in the treatment of benign prostatic hyperplasia (BPH).

Int J Urol. 1994 Sep;1(3):203-11. doi: 10.1111/j.1442-2042.1994.tb00036.x.

Alpha-blockers for the Treatment of Benign Prostatic Hyperplasia.用于治疗良性前列腺增生的α受体阻滞剂

Urol Clin North Am. 2016 Aug;43(3):311-23. doi: 10.1016/j.ucl.2016.04.009.

Alpha adrenergic antagonists for the treatment of symptomatic BPH.用于治疗有症状良性前列腺增生的α肾上腺素能拮抗剂。

Int J Clin Pharmacol Ther Toxicol. 1989 Apr;27(4):151-5.

Genetic variants in 5p13.2 and 7q21.1 are associated with treatment for benign prostatic hyperplasia with the α-adrenergic receptor antagonist.5p13.2和7q21.1区域的基因变异与α-肾上腺素能受体拮抗剂治疗良性前列腺增生有关。

Aging Male. 2017 Dec;20(4):250-256. doi: 10.1080/13685538.2017.1358261. Epub 2017 Aug 8.

Overview of alpha-blocker therapy for benign prostatic hyperplasia.α受体阻滞剂治疗良性前列腺增生概述。

Urology. 1998 Apr;51(4A Suppl):38-45. doi: 10.1016/s0090-4295(98)00054-5.

[Latest frontiers in pharmacotherapy for benign prostatic hyperplasia].[良性前列腺增生药物治疗的最新前沿进展]

Yakugaku Zasshi. 2006 Mar;126 Spec no.:199-206. doi: 10.1248/yakushi.126.199.

Alpha-blockers in the treatment of benign prostatic hypertrophy: physiological basis and review of the problem.α受体阻滞剂治疗良性前列腺增生症：生理基础及问题综述

Eur Urol. 1984;10(5):306-10. doi: 10.1159/000463816.

Expanding role of alpha adrenoceptor blockade in the treatment of benign prostatic hyperplasia.α肾上腺素能受体阻滞剂在良性前列腺增生治疗中不断扩大的作用。

Int J Clin Pract. 1998 Sep;52(6):402-7.

(Phenylpiperidinyl)cyclohexylsulfonamides: development of alpha1a/1d-selective adrenergic receptor antagonists for the treatment of benign prostatic hyperplasia/lower urinary tract symptoms (BPH/LUTS).（苯基哌啶基）环己基磺酰胺：用于治疗良性前列腺增生/下尿路症状（BPH/LUTS）的α1a/1d选择性肾上腺素能受体拮抗剂的研发

Bioorg Med Chem Lett. 2007 Jul 15;17(14):3930-4. doi: 10.1016/j.bmcl.2007.04.098. Epub 2007 May 3.

Alpha-adrenergic blocking drugs in the management of benign prostatic hyperplasia: interactions with antihypertensive therapy.α-肾上腺素能阻断药物在良性前列腺增生治疗中的应用：与抗高血压治疗的相互作用

Urology. 1999 Mar;53(3 Suppl 3a):14-20; discussion 41-2. doi: 10.1016/s0090-4295(98)00534-2.

引用本文的文献

Differential effects of the enantiomers of tamsulosin and tolterodine on P-glycoprotein and cytochrome P450 3A4.坦索罗辛和托特罗定对映体对P-糖蛋白和细胞色素P450 3A4的不同作用。

Naunyn Schmiedebergs Arch Pharmacol. 2017 Jan;390(1):49-59. doi: 10.1007/s00210-016-1304-9. Epub 2016 Sep 27.

Thermoanalytical investigation of terazosin hydrochloride.盐酸特拉唑嗪的热分析研究

Adv Pharm Bull. 2013;3(1):147-52. doi: 10.5681/apb.2013.025. Epub 2013 Feb 7.

α1-Adrenoceptors and muscarinic receptors in voiding function - binding characteristics of therapeutic agents in relation to the pharmacokinetics.α1-肾上腺素能受体和毒蕈碱受体在排尿功能中的作用——治疗药物的结合特性与药代动力学的关系。

Br J Clin Pharmacol. 2011 Aug;72(2):205-17. doi: 10.1111/j.1365-2125.2011.03922.x.

Quantification and distribution of alpha 1-adrenoceptor subtype mRNAs in human prostate: comparison of benign hypertrophied tissue and non-hypertrophied tissue.

Br J Pharmacol. 1996 Nov;119(5):797-803. doi: 10.1111/j.1476-5381.1996.tb15742.x.

Detection of alpha 1-adrenoceptor subtypes in human hypertrophied prostate by in situ hybridization.通过原位杂交检测人前列腺增生组织中的α1肾上腺素能受体亚型

Histochem J. 1996 Apr;28(4):283-8. doi: 10.1007/BF02409016.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验